Sunrest Lifescience Limited IPO
Sunrest Lifescience deals in pharmaceutical products is centered around the production and distribution of a wide range of drugs and related healthcare products. Here’s an explanation of their business model:
Product Range: The company offers a diverse range of pharmaceutical products, including capsules, tablets, syrup, ointments, gels, mouthwash, solutions, suspensions, dry powders, and toothpaste. These products cover various therapeutic categories, such as Anti-Bacterial, Anti-Diarrheal, Anti-Fungal, Anti-Malarial, Anti-Diabetic, Dental Care, Anti-Protozoal, Anti-Histamine, Anti-Hypertensive, Cosmetic, Anti-Parasitic, Multivitamin, Multimineral, Nutraceutical, and Anti-Inflammatory drugs.
Trademark and Product Portfolio: The company holds 18 registered trademarks for 32 products, indicating its commitment to brand recognition and intellectual property protection.
Distribution Model: The company distributes its products through a network that includes stockists and super stockists. These intermediaries, in turn, make the products available at various points of sale, including chemist shops, dispensaries, hospitals, etc.
Manufacturing Model: The company relies on a combination of in-house manufacturing (through their group company, Trilend Pharmaceuticals Private Limited) and third-party manufacturing. This approach allows flexibility in production and the ability to cater to specific customer requirements. They have 43 third-party manufacturers located in different states.
Location Presence: The company’s registered office is located in Ahmedabad, Gujarat, while its godown (storage facility) is situated in a different location in Ahmedabad. This dual location setup likely serves as a central hub for their operations.
Quality Assurance and Regulatory Compliance: The company places significant emphasis on product quality and regulatory compliance. They partner with manufacturers that have the necessary certifications and approvals from regulatory authorities. The company also conducts thorough checks of the manufacturer’s credibility, past product quality, and the hygiene and cleanliness of their facilities.
Quality Control: The company’s quality control department inspects products and ensures that they meet the company’s quality standards. Manufacturers are required to provide analysis reports for each batch of products, and the company rejects any products that fail to meet quality requirements.
Research & Development: The company’s focus is primarily on generic products, and they do not have their own research and development (R&D) centers. This suggests that they may not engage in extensive research for new drug development but rather focus on manufacturing and distributing existing pharmaceutical products.
Objects of the Sunrest Lifescience Limited IPO:
Sunrest Lifescience Limited IPO Details:
|Open Date:||Nov 07 2023|
|Close Date:||Nov 09 2023|
|Face Value:||₹ 10 Per Equity Share|
|Issue Type:||Fixed Price Issue IPO|
|Issue Size:||10.85 Cr.|
|Lot Size:||1600 Shares|
|Issue Price:||₹ 84 Per Equity Share|
|Listing At:||NSE Emerge|
|Listing Date:||Nov 20 2023|
Promoters And Management:
Financials of Sunrest Lifescience Limited IPO:
Particulars ( In Lakhs )
|Revenue from Operations||1,695||2,689||2,464||564|
|Purchases of Stock-in-Trade||1,240||1,824||1,652||396|
|Change in Inventories||-105||-77||-165||-178|
|Employee benefits expenses||237||254||320||91|
|Depreciation & Amortisation||4||6||13||2|
Comparison With Peers:
|Name of the Company||Revenue (In Crore)||PAT (In Crore)||EPS ( in Rs)||P/E||CMP||Mcap (In Crore)|
|Sunrest Lifescience Limited||25||2||4.76||17.6||84||36|
|Trident Lifeline Limited||32||6||5.23||32.6||195||224|
|Vaishali Pharma Limited||70||7||6.26||21.7||137||145|
|Chandra Bhagat Pharma Limited||120||1||1.21||84.0||101||76|